Travere Therapeutics, Inc. (TVTX)
NASDAQ: TVTX · Real-Time Price · USD
19.80
-1.60 (-7.48%)
Mar 3, 2025, 4:00 PM EST - Market closed
Travere Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 233.18 | 145.24 | 109.46 | 131.84 | 198.32 | Upgrade
|
| Revenue Growth (YoY) | 60.55% | 32.69% | -16.97% | -33.52% | 13.11% | Upgrade
|
| Cost of Revenue | 225.24 | 256.44 | 231.75 | 204.98 | 137.9 | Upgrade
|
| Gross Profit | 7.94 | -111.2 | -122.29 | -73.14 | 60.42 | Upgrade
|
| Selling, General & Admin | 264.12 | 265.54 | 197.52 | 126.28 | 135.8 | Upgrade
|
| Operating Expenses | 264.12 | 265.54 | 197.52 | 126.28 | 135.8 | Upgrade
|
| Operating Income | -256.18 | -376.74 | -319.81 | -199.43 | -75.38 | Upgrade
|
| Interest Expense | -11.18 | -11.33 | -11.01 | -19.68 | -19.05 | Upgrade
|
| Interest & Investment Income | 17.82 | 21.77 | 6.28 | 1.99 | 5 | Upgrade
|
| Earnings From Equity Investments | -3.4 | - | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | -0.7 | 0.5 | 1.4 | 0.3 | 1.2 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.78 | 1.09 | -0.43 | -0.07 | 0.22 | Upgrade
|
| EBT Excluding Unusual Items | -252.87 | -364.72 | -323.58 | -216.88 | -88 | Upgrade
|
| Merger & Restructuring Charges | -2.44 | -11.39 | - | - | - | Upgrade
|
| Other Unusual Items | - | - | -7.58 | - | -3.66 | Upgrade
|
| Pretax Income | -320.51 | -376.11 | -331.16 | -216.88 | -188.79 | Upgrade
|
| Income Tax Expense | 0.12 | 0.22 | 0.31 | 0.41 | -19.36 | Upgrade
|
| Earnings From Continuing Operations | -320.63 | -376.33 | -331.47 | -217.29 | -169.43 | Upgrade
|
| Earnings From Discontinued Operations | -0.92 | 264.93 | 52.99 | 37.2 | - | Upgrade
|
| Net Income | -321.55 | -111.4 | -278.48 | -180.09 | -169.43 | Upgrade
|
| Net Income to Common | -321.55 | -111.4 | -278.48 | -180.09 | -169.43 | Upgrade
|
| Shares Outstanding (Basic) | 79 | 74 | 64 | 60 | 48 | Upgrade
|
| Shares Outstanding (Diluted) | 79 | 74 | 64 | 60 | 48 | Upgrade
|
| Shares Change (YoY) | 6.22% | 16.48% | 6.56% | 25.86% | 12.28% | Upgrade
|
| EPS (Basic) | -4.08 | -1.50 | -4.37 | -3.01 | -3.56 | Upgrade
|
| EPS (Diluted) | -4.08 | -1.50 | -4.37 | -3.01 | -3.56 | Upgrade
|
| Free Cash Flow | -237.48 | -280.02 | -186.29 | -19.89 | -49.51 | Upgrade
|
| Free Cash Flow Per Share | -3.01 | -3.77 | -2.92 | -0.33 | -1.04 | Upgrade
|
| Gross Margin | 3.40% | -76.57% | -111.72% | -55.48% | 30.47% | Upgrade
|
| Operating Margin | -109.87% | -259.40% | -292.17% | -151.27% | -38.01% | Upgrade
|
| Profit Margin | -137.90% | -76.70% | -254.41% | -136.60% | -85.43% | Upgrade
|
| Free Cash Flow Margin | -101.84% | -192.80% | -170.19% | -15.09% | -24.96% | Upgrade
|
| EBITDA | -212.63 | -338.21 | -299.09 | -186.68 | -50.8 | Upgrade
|
| EBITDA Margin | -91.19% | -232.87% | -273.25% | -141.60% | -25.61% | Upgrade
|
| D&A For EBITDA | 43.56 | 38.53 | 20.72 | 12.75 | 24.58 | Upgrade
|
| EBIT | -256.18 | -376.74 | -319.81 | -199.43 | -75.38 | Upgrade
|
| EBIT Margin | -109.87% | -259.40% | -292.17% | -151.27% | -38.01% | Upgrade
|
| Revenue as Reported | 233.18 | 145.24 | 109.46 | 131.84 | 198.32 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.